Summary of Study ST001018

This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR000680. The data can be accessed directly via it's Project DOI: 10.21228/M8S684 This work is supported by NIH grant, U2C- DK119886.

See: https://www.metabolomicsworkbench.org/about/howtocite.php

This study contains a large results data set and is not available in the mwTab file. It is only available for download via FTP as data file(s) here.

Show all samples | Perform analysis on untargeted data
Download mwTab file (text) | Download mwTab file(JSON) | Download data files

Study ID	ST001018
Study Title	Large Scale Profiling in Serum for Muscle Wasting in Cancer Cachexia (part-XII)
Study Summary	Large Scale Profiling of muscle wasting in Cancer Cachexia. Serum samples from 10 control patients, 10 weight stable pancreatic cancer patients, and 10 pancreatic cancer patients with significant weight loss. Samples are divided evenly between males and females.
Institute	Mayo Clinic
Last Name	Guttridge
First Name	Denis
Address	520 Biomedical Research Tower 460 W. 12th Avenue Columbus, OH 43210
Email	denis.guttridge@osumc.edu
Phone	614-688-3137
Submit Date	2018-07-15
Analysis Type Detail	LC-MS
Release Date	2020-07-15
Release Version	1

Select appropriate tab below to view additional metadata details:

Project:

Project ID:	PR000680
Project DOI:	doi: 10.21228/M8S684
Project Title:	Mayo Pilot and Feasibility: Metabolomics of Muscle Wasting in Cancer Cachexia
Project Summary:	Cachexia is a debilitating syndrome that results in severe, involuntary weight loss due to the depletion of skeletal muscle mass. This syndrome occurs in a majority of cancers and contributes to approximately one third of all cancer deaths. Currently, no effective therapy exists to combat this malignant disorder, and disappointing results from recent Phase III clinical trials indicate that a cachexia treatment is not likely to appear soon. Thus, it is clear that greater knowledge of the mechanisms driving muscle wasting in cachexia is needed in order to identify new therapeutic targets and stimulate new clinical trials. Our approach to gaining this knowledge has been to work with muscle biopsies from pancreatic cancer patients, since this population is highly prone to cachexia. We have also been expanding our studies beyond the classical mouse models of cancer cachexia in hopes of finding a new model that better recapitulates the human disease. We recently undertook RNA-Seq analysis comparing muscle biopsies from pancreatic cancer patients with and without cachexia, which has been exciting since this type of analysis has not yet been performed in patient samples. Preliminary results revealed that cachectic muscle was associated with alterations in metabolism. These data provide the rationale for performing metabolomics to ascertain whether specific metabolic pathways or metabolites can be identified as potential drivers of muscle wasting in cachexia or be used as biomarker of cachexia, which the field desperately needs. An additional need is a well-validated animal model of cancer cachexia that accurately reflects the human condition, which can be used to test mechanisms and pre-clinical compounds. We propose to perform these studies under the Mayo Clinic Metabolomics Resource Core Pilot and Feasibility Grant program to: 1) Identify metabolic alterations and biomarkers of pancreatic cancer-induced muscle wasting; and 2) Identify a suitable mouse model that recapitulates the metabolic imbalance of muscles from pancreatic cancer cachexia patients. By performing these studies, we will accelerate our understanding of the underlying causes of muscle wasting, which should translate to improving the current pipeline of anticachexia therapies.
Institute:	Mayo Clinic
Last Name:	Guttridge
First Name:	Denis
Address:	520 Biomedical Research Tower 460 W. 12th Avenue Columbus, OH 43210
Email:	denis.guttridge@osumc.edu
Phone:	614-688-3137

Subject:

Subject ID:	SU001057
Subject Type:	Human
Subject Species:	Homo sapiens
Taxonomy ID:	9606

Factors:

Subject type: Human; Subject species: Homo sapiens (Factor headings shown in green)

mb_sample_id	local_sample_id	Groups	Gender
SA063822	philic-30may17-007	Control	Female
SA063823	philic-30may17-004	Control	Female
SA063824	philic-30may17-009	Control	Female
SA063825	philic-30may17-018	Control	Female
SA063826	nC18-31may17-018	Control	Female
SA063827	philic-30may17-003	Control	Female
SA063828	pC18-30may17-009	Control	Female
SA063829	pC18-30may17-003	Control	Female
SA063830	pC18-30may17-004	Control	Female
SA063831	pC18-30may17-007	Control	Female
SA063832	nhilic-31may17-018	Control	Female
SA063833	nhilic-31may17-007	Control	Female
SA063834	nhilic-31may17-009	Control	Female
SA063835	nC18-31may17-009	Control	Female
SA063836	nC18-31may17-007	Control	Female
SA063837	nC18-31may17-004	Control	Female
SA063838	nC18-31may17-003	Control	Female
SA063839	nhilic-31may17-003	Control	Female
SA063840	pC18-30may17-018	Control	Female
SA063841	nhilic-31may17-004	Control	Female
SA063842	nhilic-31may17-020	Control	Male
SA063843	pC18-30may17-015	Control	Male
SA063844	pC18-30may17-027	Control	Male
SA063845	nhilic-31may17-010	Control	Male
SA063846	pC18-30may17-020	Control	Male
SA063847	nhilic-31may17-015	Control	Male
SA063848	nhilic-31may17-002	Control	Male
SA063849	pC18-30may17-010	Control	Male
SA063850	pC18-30may17-002	Control	Male
SA063851	nC18-31may17-027	Control	Male
SA063852	nC18-31may17-015	Control	Male
SA063853	philic-30may17-010	Control	Male
SA063854	philic-30may17-020	Control	Male
SA063855	nC18-31may17-010	Control	Male
SA063856	nC18-31may17-002	Control	Male
SA063857	philic-30may17-027	Control	Male
SA063858	nC18-31may17-020	Control	Male
SA063859	philic-30may17-015	Control	Male
SA063860	nhilic-31may17-027	Control	Male
SA063861	philic-30may17-002	Control	Male
SA063862	philic-30may17-029	Weight Losing	Female
SA063863	nC18-31may17-001	Weight Losing	Female
SA063864	nhilic-31may17-026	Weight Losing	Female
SA063865	pC18-30may17-029	Weight Losing	Female
SA063866	nhilic-31may17-021	Weight Losing	Female
SA063867	philic-30may17-022	Weight Losing	Female
SA063868	nhilic-31may17-022	Weight Losing	Female
SA063869	philic-30may17-001	Weight Losing	Female
SA063870	pC18-30may17-026	Weight Losing	Female
SA063871	nhilic-31may17-029	Weight Losing	Female
SA063872	philic-30may17-021	Weight Losing	Female
SA063873	philic-30may17-026	Weight Losing	Female
SA063874	nhilic-31may17-001	Weight Losing	Female
SA063875	pC18-30may17-021	Weight Losing	Female
SA063876	nC18-31may17-022	Weight Losing	Female
SA063877	nC18-31may17-029	Weight Losing	Female
SA063878	nC18-31may17-026	Weight Losing	Female
SA063879	pC18-30may17-001	Weight Losing	Female
SA063880	pC18-30may17-022	Weight Losing	Female
SA063881	nC18-31may17-021	Weight Losing	Female
SA063882	nhilic-31may17-030	Weight Losing	Male
SA063883	nhilic-31may17-014	Weight Losing	Male
SA063884	pC18-30may17-005	Weight Losing	Male
SA063885	nC18-31may17-030	Weight Losing	Male
SA063886	philic-30may17-006	Weight Losing	Male
SA063887	philic-30may17-013	Weight Losing	Male
SA063888	philic-30may17-014	Weight Losing	Male
SA063889	nC18-31may17-014	Weight Losing	Male
SA063890	nhilic-31may17-013	Weight Losing	Male
SA063891	philic-30may17-005	Weight Losing	Male
SA063892	nC18-31may17-013	Weight Losing	Male
SA063893	pC18-30may17-006	Weight Losing	Male
SA063894	nhilic-31may17-006	Weight Losing	Male
SA063895	nC18-31may17-006	Weight Losing	Male
SA063896	nhilic-31may17-005	Weight Losing	Male
SA063897	pC18-30may17-030	Weight Losing	Male
SA063898	nC18-31may17-005	Weight Losing	Male
SA063899	philic-30may17-030	Weight Losing	Male
SA063900	pC18-30may17-013	Weight Losing	Male
SA063901	pC18-30may17-014	Weight Losing	Male
SA063902	nhilic-31may17-016	Weight Stable	Female
SA063903	nC18-31may17-019	Weight Stable	Female
SA063904	nhilic-31may17-017	Weight Stable	Female
SA063905	pC18-30may17-019	Weight Stable	Female
SA063906	pC18-30may17-017	Weight Stable	Female
SA063907	philic-30may17-019	Weight Stable	Female
SA063908	nC18-31may17-016	Weight Stable	Female
SA063909	philic-30may17-016	Weight Stable	Female
SA063910	nC18-31may17-017	Weight Stable	Female
SA063911	pC18-30may17-024	Weight Stable	Female
SA063912	philic-30may17-025	Weight Stable	Female
SA063913	pC18-30may17-016	Weight Stable	Female
SA063914	philic-30may17-024	Weight Stable	Female
SA063915	pC18-30may17-025	Weight Stable	Female
SA063916	philic-30may17-017	Weight Stable	Female
SA063917	nhilic-31may17-024	Weight Stable	Female
SA063918	nhilic-31may17-019	Weight Stable	Female
SA063919	nC18-31may17-024	Weight Stable	Female
SA063920	nC18-31may17-025	Weight Stable	Female
SA063921	nhilic-31may17-025	Weight Stable	Female

Showing page 1 of 2 Results: 1 2 Next Showing results 1 to 100 of 120

Collection:

Collection ID:	CO001051
Collection Summary:	Tissue and blood donated from Cancer Cachexia Program at Ohio State University
Sample Type:	Blood (serum)

Treatment:

Treatment ID:	TR001071
Treatment Summary:	Cancer cachexia is a multi-factorial syndrome accompanying advanced cancer, with the most notable symptom being unintentional weight loss. Cachectic patients lose both adipose tissue and skeletal muscle, with skeletal muscle loss and its associated weakness contributing to the morbidity and mortality of these patients. Despite three decades of research into mechanisms driving muscle wasting due to cancer, to date, an approved pharmacological therapy to prevent or treat cancer cachexia is still lacking. Our laboratory focuses on cancer cachexia in patients with pancreatic cancer, as up to 85% of these patients experience weight loss. Cachexia often occurs early in the progression of pancreatic cancer, making clear that cachexia in these patients is not simply a result of end-stage disease. Further, with perhaps more than ¼ of all pancreatic cancer deaths resulting from muscle weakness as opposed to tumor burden, cachexia also significantly contributes to mortality due to pancreatic cancer. Because little progress has been made in improving treatment outcomes, addressing cancer-induced muscle wasting is perhaps the best strategy to prolong pancreatic cancer patient survival and increase patient quality of life. In an effort to better understand the mechanisms driving pancreatic cancer-induced muscle wasting, the Cancer Cachexia Program at Ohio State University has begun a Pancreatic Cancer Cachexia Tissue Bank. To date, over 130 patients undergoing attempted resection for pancreatic cancer or other abdominal surgeries have donated muscle and blood to our bank. A unique aspect of our tissue bank is our focus on patients eligible for resection. In contrast to other studies using patients with late-stage disease, our patients are not end-stage, as they are considered healthy enough to undergo a major operation.

Treatment ID:

TR001071

Treatment Summary:

Cancer cachexia is a multi-factorial syndrome accompanying advanced cancer, with the most notable symptom being unintentional weight loss. Cachectic patients lose both adipose tissue and skeletal muscle, with skeletal muscle loss and its associated weakness contributing to the morbidity and mortality of these patients. Despite three decades of research into mechanisms driving muscle wasting due to cancer, to date, an approved pharmacological therapy to prevent or treat cancer cachexia is still lacking. Our laboratory focuses on cancer cachexia in patients with pancreatic cancer, as up to 85% of these patients experience weight loss. Cachexia often occurs early in the progression of pancreatic cancer, making clear that cachexia in these patients is not simply a result of end-stage disease. Further, with perhaps more than ¼ of all pancreatic cancer deaths resulting from muscle weakness as opposed to tumor burden, cachexia also significantly contributes to mortality due to pancreatic cancer. Because little progress has been made in improving treatment outcomes, addressing cancer-induced muscle wasting is perhaps the best strategy to prolong pancreatic cancer patient survival and increase patient quality of life. In an effort to better understand the mechanisms driving pancreatic cancer-induced muscle wasting, the Cancer Cachexia Program at Ohio State University has begun a Pancreatic Cancer Cachexia Tissue Bank. To date, over 130 patients undergoing attempted resection for pancreatic cancer or other abdominal surgeries have donated muscle and blood to our bank. A unique aspect of our tissue bank is our focus on patients eligible for resection. In contrast to other studies using patients with late-stage disease, our patients are not end-stage, as they are considered healthy enough to undergo a major operation.

Sample Preparation:

Sampleprep ID:	SP001064
Sampleprep Summary:	large scale profiling using serum

Combined analysis:

Analysis ID	AN001663	AN001664	AN001665	AN001666
Analysis type	MS	MS	MS	MS
Chromatography type	HILIC	HILIC	Reversed phase	Reversed phase
Chromatography system	Agilent 1290 Infinity	Agilent 1290 Infinity	Agilent 1290 Infinity	Agilent 1290 Infinity
Column	Waters Acquity BEH Amide (150 x 2.1mm,1.7um)	Waters Acquity BEH Amide (150 x 2.1mm,1.7um)	Waters Acquity HSS C18 (150 x 2.1mm,1.8um)	Waters Acquity HSS C18 (150 x 2.1mm,1.8um)
MS Type	ESI	ESI	ESI	ESI
MS instrument type	QTOF	QTOF	QTOF	QTOF
MS instrument name	Agilent 6550 QTOF	Agilent 6550 QTOF	Agilent 6550 QTOF	Agilent 6550 QTOF
Ion Mode	POSITIVE	NEGATIVE	POSITIVE	NEGATIVE
Units	intensity	intensity	intensity	intensity

Chromatography:

Chromatography ID:	CH001172
Instrument Name:	Agilent 1290 Infinity
Column Name:	Waters Acquity BEH Amide (150 x 2.1mm,1.7um)
Chromatography Type:	HILIC

Chromatography ID:	CH001173
Instrument Name:	Agilent 1290 Infinity
Column Name:	Waters Acquity HSS C18 (150 x 2.1mm,1.8um)
Chromatography Type:	Reversed phase

MS:

MS ID:	MS001538
Analysis ID:	AN001663
Instrument Name:	Agilent 6550 QTOF
Instrument Type:	QTOF
MS Type:	ESI
Ion Mode:	POSITIVE

MS ID:	MS001539
Analysis ID:	AN001664
Instrument Name:	Agilent 6550 QTOF
Instrument Type:	QTOF
MS Type:	ESI
Ion Mode:	NEGATIVE

MS ID:	MS001540
Analysis ID:	AN001665
Instrument Name:	Agilent 6550 QTOF
Instrument Type:	QTOF
MS Type:	ESI
Ion Mode:	POSITIVE

MS ID:	MS001541
Analysis ID:	AN001666
Instrument Name:	Agilent 6550 QTOF
Instrument Type:	QTOF
MS Type:	ESI
Ion Mode:	NEGATIVE